alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
EXHIBIT 10.2



 Exhibit 10.2 
 WAIVER 
 In consideration for the benefits I will receive as a result of my employer’s participation in
the United States Department of the Treasury’s TARP Capital Purchase Program, I hereby voluntarily waive any claim against the United States or my employer for any changes to my compensation or benefits that are required to comply with the
regulation issued by the Department of the Treasury as published in the Federal Register on October 20, 2008. 
 I acknowledge that this regulation may
require modification of the compensation, bonus, incentive and other benefit plans, arrangements, policies and agreements (including so-called “golden parachute” agreements) that I have with my employer or in which I participate as they
relate to the period the United States holds any equity or debt securities of my employer acquired through the TARP Capital Purchase Program. 
 This waiver
includes all claims I may have under the laws of the United States or any state related to the requirements imposed by the aforementioned regulation, including without limitation a claim for any compensation or other payments I would otherwise
receive, any challenge to the process by which this regulation was adopted and any tort or constitutional claim about the effect of these regulations on my employment relationship. 
  

			
	Date: January 16, 2009	 	  

		 	Signature
		
		 	  

		 	Print Name
		
		 	  

		 	Title
Kenterrio RIORDAN, Appellant/Petitioner(s), v. STATE of Florida, Appellee/Respondent(s).

CASE NO.: 2D19-1796

District Court of Appeal of Florida, Second District.

May 15, 2019

**DECISION WITHOUT PUBLISHED OPINION**

Denied.
**Exhibit 32.1**

 

**SECTION 1350 CERTIFICATION**

 

I, Ronald G. Farrell, Chairman of the Board and ChiefExecutive Officer of Tri-S Security Corporation (the “Company”), do herebycertify in accordance with 18 U.S.C. §1350, as adopted pursuant to Section 906of the Sarbanes-Oxley Act of 2002, that, to my knowledge:

 

1.                                       The Quarterly Report on Form10-Q/A of the Company for the period ended March 31, 2005 (the “PeriodicReport”) fully complies with the requirements of section 13(a) or 15(d) ofthe Securities Exchange Act of 1934 (15 U.S.C. §§78m or 78o(d)); and

 

2.                                       The information contained inthe Periodic Report fairly presents, in all material respects, the financialcondition and results of operations of the Company.

 
| Dated: November 17, 2005 |                    |
|--------------------------|-------------------------|
|                     |                    |
|                     | /s/Ronald G. Farrell    |   |
|                     | Ronald G. Farrell,      |
|                     | Chief Executive Officer |

 

----
# L_2017003EN.01003101.xml

| 6.1.2017 | EN | Official Journal of the European Union | L 3/31 |
| --- | --- | --- | --- |

6.1.2017

EN

Official Journal of the European Union

L 3/31

---

COMMISSION IMPLEMENTING REGULATION (EU) 2017/8

of 5 January 2017

on the minimum selling price for skimmed milk powder for the second partial invitation to tender within the tendering procedure opened by Implementing Regulation (EU) 2016/2080

THE EUROPEAN COMMISSION,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EU) No 1308/2013 of the European Parliament and of the Council of 17 December 2013 establishing a common organisation of the markets in agricultural products and repealing Council Regulations (EEC) No 922/72, (EEC) No 234/79, (EC) No 1037/2001 and (EC) No 1234/2007 (1),

Having regard to Commission Implementing Regulation (EU) 2016/1240 of 18 May 2016 laying down rules for the application of Regulation (EU) No 1308/2013 of the European Parliament and of the Council with regard to public intervention and aid for private storage (2), and in particular Article 32 thereof,

Whereas:

| (1) | Commission Implementing Regulation (EU) 2016/2080 (3) has opened the sale of skimmed milk powder by a tendering procedure. |
| --- | --- |

(1)

Commission Implementing Regulation (EU) 2016/2080 (3) has opened the sale of skimmed milk powder by a tendering procedure.

| (2) | In the light of the tenders received for the second partial invitation to tender, a minimum selling price should not be fixed. |
| --- | --- |

(2)

In the light of the tenders received for the second partial invitation to tender, a minimum selling price should not be fixed.

| (3) | The measures provided for in this Regulation are in accordance with the opinion of the Committee for the Common Organisation of the Agricultural Markets, |
| --- | --- |

(3)

The measures provided for in this Regulation are in accordance with the opinion of the Committee for the Common Organisation of the Agricultural Markets,

HAS ADOPTED THIS REGULATION:

Article 1

For the second partial invitation to tender for the selling of skimmed milk powder within the tendering procedure opened by Implementing Regulation (EU) 2016/2080, in respect of which the period during which tenders were to be submitted ended on 3 January 2017, a minimum selling price has not been fixed.

Article 2

This Regulation shall enter into force on the day of its publication in the Official Journal of the European Union.

This Regulation shall be binding in its entirety and directly applicable in all Member States.

Done at Brussels, 5 January 2017.

For the Commission,

On behalf of the President,

Jerzy PLEWA

Director-General

Directorate-General for Agriculture and Rural Development

---

(1)  
  OJ L 347, 20.12.2013, p. 671.

1

(2)  
  OJ L 206, 30.7.2016, p. 71.

2

(3)  Commission Implementing Regulation (EU) 2016/2080 of 25 November 2016 opening the sale of skimmed milk powder by a tendering procedure (OJ L 321, 29.11.2016, p. 45).

3

---
Marcus Maurice PRINCE v. STATE

CR-16-1174

Court of Criminal Appeals of Alabama.

February 2, 2018

**DECISION WITHOUT PUBLISHED OPINION**

Affirmed.
In the United States Court of Federal Claims 

OFFICE OF SPECIAL MASTERS

No. 21-0617V

UNPUBLISHED

THOMAS MEIROSE,

 Petitioner,

v.

SECRETARY OF HEALTH AND 

HUMAN SERVICES,

 Respondent.

Chief Special Master Corcoran 

Filed: May 19, 2022

Special Processing Unit (SPU); 

Ruling on Entitlement; Concession;

Table Injury; Influenza (Flu) Vaccine;

Shoulder Injury Related to Vaccine 

Administration (SIRVA)

Paul R. Brazil, Muller Brazil, LLP, Dresher, PA, for Petitioner.

Zoe Wade, U.S. Department of Justice, Washington, DC, for Respondent.

RULING ON ENTITLEMENT1

On January 12, 2021, Thomas Meirose filed a petition for compensation under the 

National Vaccine Injury Compensation Program, 42 U.S.C. § 300aa-10, et seq.2(the 

“Vaccine Act”). Petitioner alleges that he suffered a left shoulder injury related to vaccine 

administration (“SIRVA”) as a result of an influenza (“flu”) vaccine administered on 

October 26, 2018. Petition at 1. The case was assigned to the Special Processing Unit of 

the Office of Special Masters.

On May 19, 2022, Respondent filed his Rule 4(c) report in which he concedes that 

Petitioner is entitled to compensation in this case. Respondent’s Rule 4(c) Report at 1.

Specifically, Respondent agrees that Petitioner has satisfied the criteria set forth in the 

Vaccine Injury Table (“Table”) and the Qualifications and Aids to Interpretation (“QAI”) for 

1 Because this unpublished Ruling contains a reasoned explanation for the action in this case, I am required 

to post it on the United States Court of Federal Claims' website in accordance with the E-Government Act 

of 2002. 44 U.S.C. § 3501 note (2012) (Federal Management and Promotion of Electronic Government 

Services). This means the Ruling will be available to anyone with access to the internet. In accordance 

with Vaccine Rule 18(b), Petitioner has 14 days to identify and move to redact medical or other information, 

the disclosure of which would constitute an unwarranted invasion of privacy. If, upon review, I agree that 

the identified material fits within this definition, I will redact such material from public access. 

2 National Childhood Vaccine Injury Act of 1986, Pub. L. No. 99-660, 100 Stat. 3755. Hereinafter, for ease 

of citation, all section references to the Vaccine Act will be to the pertinent subparagraph of 42 U.S.C. § 

300aa (2012).
2

SIRVA. Id. at 9 (citing 42 C.F. R. § 100.3(a)(XIV)(B), (c)(10). Respondent further agrees 

that the case was timely filed; that the vaccine was received in the United States; and that 

Petitioner satisfies the statutory severity requirement by suffering the residual effects or 

complications of her injury for more than six months after vaccine administration. Id.

(citing Vaccine Act sections 11(c)(1)(B)(i)(I) and 11(c)(1)(D)(i)).

In view of Respondent’s position and the evidence of record, I find that 

Petitioner is entitled to compensation.

IT IS SO ORDERED.

s/Brian H. Corcoran

Brian H. Corcoran

Chief Special Master
Exhibit 33.1 REPORT ON ASSESSMENT OF COMPLIANCE WITH REGULATION AB SERVICING CRITERIA U.S. Bank Trust National Association (the "Trustee"), in respect of the STRATSSM Trust for AMBAC Financial Group, Inc. Securities, Series 2007-1, is responsible for assessing compliance as of December 31, 2008 and for the period from and including January 1, 2008 through and including December 31, 2008 (the "Reporting Period") with the servicing criteria set forth in
            Item 1122(d) of the Securities and Exchange Commission's Regulation AB (the "Applicable Servicing Criteria"). The Trustee has assessed its compliance with the Applicable Servicing Criteria for the Reporting Period and has concluded that the Trustee has complied, in all material respects, with the Applicable Servicing Criteria as of December 31, 2008 and for the Reporting Period. Ernst & Young LLP, CPA, an independent registered public accounting firm, has issued an attestation report on the assessment of compliance with the Applicable Servicing Criteria as of December 31, 2008 and for the Reporting Period as set forth in this assertion. U.S. Bank Trust National Association, as Trustee   By: /s/ Janet P. O'Hara                                                  Date: 
                3/11/2009
                        Name:  Janet P. O'Hara Title:  Assistant Vice President
LETTER AGREEMENT



 



Exhibit 10.2



	 	151 Farmington Avenue

Hartford, CT 06156




	 	 	 
	 	 	
John W. Rowe, M.D.
	 	 	
Chairman & CEO
	 	 	
860-273-4455
	June 30, 2003	 	
Fax: 860-273-6872



David B. Kelso


Dear David:



In order to facilitate the continuation of our discussions, I believe that we
should change the notice period applicable to the extension of your employment
agreement. Accordingly, this letter is to evidence our mutual agreement to
reduce the 90 day written notice period specified in Section 1.02 of that
certain Employment Agreement dated as of September 13, 2001 by and between you
and the Company to a period of 30 days.


All capitalized terms used herein shall have the same meanings as set forth in
the Agreement.


Sincerely,



/s/: John W. Rowe


John W. Rowe, M.D.


Agreed:


/s/: David B. Kelso




David B. Kelso

/s/: 6/30/03




Date
##### 



Exhibit 10.19





|2008 Executive Incentive Plan
|-----------------------------



---



##### 



|Incentive Structure

 Quarterly weightings

 Metrics

 Weighting of metrics

 Target setting

 Target leverage and ranges

 First half 2008 targets
|---------------------------------------------------------------------------------------------------------------------------------------------------



---



##### 



|Quarterly Weightings

Q1 25% of annual target

Q2 25% of annual target

Q3 25% of annual target

Q4 25% of annual target
|------------------------------------------------------------------------------------------------------------------------



---



##### 



|Metrics

AMRG

Defined as average monthly "gross" revenue growth during a
quarter

EBITDA

Defined as GAAP operating income plus depreciation and
amortization plus non-cash stock based compensation

Individual MBOs

MBOs must be specific, measurable, attainable, realistic and
time-based
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



---



##### 



|Weighting of Metrics

 Weighting of metrics - CEO

AMRG - 70%

EBITDA  - 30%



 Weighting of metrics - Vice Presidents

AMRG - 50%

EBITDA  - 20%

Individual MBOs  - 30%
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------



---



##### 



|Target Setting

AMRG set equal to budget / reforecast levels

Set at beginning of year and mid-year



EBITDA set equal to budget / reforecast levels

Set at beginning of year and mid-year



Individual MBOs

Set at beginning of quarter
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



---



##### 



|Target Leverage and Ranges

AMRG

Minimum threshold 85%; payout of 50% of target

Maximum threshold 135%; payout of 217% of target

Each 1% above 85% increases payout by 3.333%

EBITDA margin

Minimum threshold 95%; payout of 95% of target

Maximum threshold 105%; payout of 105% of target

Each 1% above 95% increases payout by 1%

MBOs

No minimum threshold

Maximum threshold 100%

Payout equal to % attainment of target
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



---



##### 



|Target Leverage and Ranges
|--------------------------
James Thomas STIMPSON v. STATE

CR-17-0017

Court of Criminal Appeals of Alabama.

January 30, 2018

**DECISION WITHOUT PUBLISHED OPINION**

Reversed and remanded.
**EXHIBIT 32.1****CERTIFICATION OF CHIEF EXECUTIVE OFFICER****Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (18 U.S.C. 1350)**     The undersigned executive officer of TD Banknorth Inc. (the “Registrant”) hereby certifiesthat the Registrant’s Form 10-Q for the three months ended September 30, 2006 fully complies withthe requirements of Section 13(a) of the Securities Exchange Act of 1934 and that the informationcontained therein fairly presents, in all material respects, the financial condition and results ofoperations of the Registrant.                                                                /s/ William J. Ryan   Name:William J. Ryan    Title:Chief Executive Officer   Date: November 3, 2006Note: A signed original of this written statement required by Section 906 of the Sarbanes-OxleyAct of 2002 has been provided to TD Banknorth Inc. and will be retained by TD Banknorth Inc. andfurnished to the Securities and Exchange Commission or its staff upon request.
SYLVITE SOUTHEAST, LLC, n/k/a Sylvite, LLC, a Florida Limited Liability Company, Petitioner, v. URALKALI TRADING, S.A., a foreign entity, and Uralkali Trading, SIA, LLC, a foreign entity, Respondent.

Case No. 2D18-3635

District Court of Appeal of Florida, Second District.

Opinion filed June 14, 2019.

**DECISION WITHOUT PUBLISHED OPINION**

Denied.
United States District Court

For the Northern District of California

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

IN THE UNITED STATES DISTRICT COURT

FOR THE NORTHERN DISTRICT OF CALIFORNIA

CHIRON CORPORATION,

Plaintiff,

 v.

SOURCECF INC., SOURCECF CLINICAL

RESEARCH & DEVELOPMENT, L.L.C.,

MAXOR NATIONAL PHARMACY SERVICES

CORPORATION d/b/a IV SOLUTIONS,

FOUNDATION CARE L.L.C., and

PHARMACEUTICAL SPECIALTIES, INC.,

Defendant. /

No. C 05-01938 WHA

REQUEST FOR BRIEFING

The hearing on the pending cross-motions is currently scheduled for NOVEMBER 30,

2005 AT 2 P.M. Pursuant to Civil Local Rule 7–3, opposition briefs were due 21 days before the

hearing (i.e., on November 9) and any reply briefs were due 14 days before the hearing (i.e., on

November 16). Yet, neither reply brief has been submitted and the opposition to plaintiff’s

motion for judgment was only filed yesterday.

In addition, the Court is extremely disappointed that the parties jointly represented that

no claim construction was necessary because there was no dispute regarding any claim term,

phrases or clauses. Both the technology tutorial and Markman hearing were taken off calendar

in light of this joint representation. They will not be rescheduled. Accordingly, any briefing

concerning the proper construction of the phrase “about 60 mg/ml” must be incorporated into

Case 3:05-cv-01938-WHA Document 49 Filed 11/17/05 Page 1 of 2
United States District Court

For the Northern District of California

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

2

the reply briefs to the pending motions, which must be filed no later than NOVEMBER 22, 2005

AT NOON. 

If the parties are able to resolve this dispute without the Court’s assistance, a stipulated

dismissal of all claims may be filed in lieu of reply briefs. In any event, the parties shall jointly

update the Court on the status of their settlement discussions on or before NOVEMBER 23, 2005.

IT IS SO ORDERED.

Dated: November 17, 2005 

WILLIAM ALSUP

UNITED STATES DISTRICT JUDGE

Case 3:05-cv-01938-WHA Document 49 Filed 11/17/05 Page 2 of 2
EXHIBIT 32.01

                  CERTIFICATION BY CHIEF EXECUTIVE OFFICER &

                            CHIEF FINANCIAL OFFICER

I, Michael Pacult, the Chief Executive Officer and Chief Financial Officer of
TriView Capital Management, Inc. as managing member of TriView Global Fund,
LLC, certify that (i) the Form 10-Q for the period ended March 31, 2009 of
TriView Global Fund, LLC fully complies with the requirements of Section 13(a)
or 15(d) of the Securities Exchange Act of 1934 and (ii) the information
contained in the Form 10-Q for the period ended March 31, 2009 fairly
presents, in all material respects, the financial condition and results of
operations of TriView Global Fund, LLC.



TRIVIEW GLOBAL FUND, LLC
By:	TriView Capital Management, Inc., Managing Member


By: /s/ Michael Pacult
Michael Pacult
Chief Executive Officer &
Chief Financial Officer

Date:	May 20, 2009

<page>
Joshua E. ROSE, Former Husband, Appellant, v. Chrisanna L. ROSE, Former Wife, Appellee.

No. 1D19-164

District Court of Appeal of Florida, First District.

June 26, 2019

**DECISION WITHOUT PUBLISHED OPINION**

Affirmed.
IN THE SUPREME COURT OF PENNSYLVANIA

MIDDLE DISTRICT

COMMONWEALTH OF PENNSYLVANIA,

Respondent

v.

PRITAM RAJ

- SHARM KANDEL,

Petitioner :

:

:

:

:

:

:

:

:

:

: No. 237 MAL 2023

Petition for Allowance of Appeal

from the Order of the Superior Court

ORDER

PER CURIAM

AND NOW , this 5th day of March, 2024

, the Petition for Allowance of Appeal is

DENIED

.
**EXHIBIT 32.1**

 

**CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,**

**AS ADOPTED PURSUANT TO SECTION 906**

**OF THE SARBANES-OXLEY ACT OF 2002**

 

Pursuantto 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of theSarbanes-Oxley Act of 2002 (“Section 906”), Robert J. Currey and Steven L.Childers, President and Chief Executive Officer and Chief Financial Officer,respectively, of Consolidated Communications Holdings, Inc., each certifythat to his knowledge (i) the Quarterly Report on Form 10-Q for thequarter ended September 30, 2010 fully complies with the requirements of Section 13(a) or15(d) of the Securities Exchange Act of 1934, as amended and (ii) theinformation contained in such report fairly presents, in all material respects,the financial condition and results of operations of ConsolidatedCommunications Holdings, Inc.

 
|   | /s/  Robert J. Currey                                       |
|--------|-------------------------------------------------------------|
|   | Robert  J. Currey                                           |
|   | President  and Chief Executive Officer                      |
|   | (Principal  Executive Officer)                              |
|   | November 5,  2010                                      |
|   |                                                        |
|   | /s/  Steven L. Childers                                     |
|   | Steven  L. Childers                                         |
|   | Senior  Vice President and Chief Financial Officer          |
|   | (Principal  Financial Officer and Chief Accounting Officer) |
|   | November 5,  2010                                      |

 

1

----
EX PARTE Aaron Lamont JOHNSON

CR-17-0273

Court of Criminal Appeals of Alabama.

January 29, 2018

**DECISION WITHOUT PUBLISHED OPINION**

Mand. pet. denied.
James L. RICHARDSON, Appellant, v. STATE of Florida, Appellee.

No. 1D18-0742

District Court of Appeal of Florida, First District.

May 21, 2019

Andy Thomas, Public Defender, and Steven L. Seliger, Assistant Public Defender, Tallahassee, for Appellant.

Ashley Moody, Attorney General, and Jennifer J. Moore, Assistant Attorney General, Tallahassee, for Appellee.

Per Curiam.

AFFIRMED .

Makar, Osterhaus, and Bilbrey, JJ., concur.
**EXHIBIT 32.2****CERTIFICATION PURSUANT TO 18 U.S.C.SECTION 1350,****AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEYACT OF 2002**     Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002and in connection with the Annual Report of onForm 10-K ofChoicePoint Inc. (the “Company”) for the year endedDecember 31, 2005, as filed with the Securities andExchange Commission on the date hereof (the “Report”),the undersigned, the Chief Financial Officer of the Company,certifies that: Based on my knowledge,     (1) The Report fully complies with the requirements ofSection 13(a) or 15(d) of the Securities Exchange Act of1934, as amended; and     (2) The information contained in the Report fairlypresents, in all material respects, the financial condition andresult of operations of the Company.     /s/ David E. Trine       David E. Trine     Chief Financial OfficerMarch 13, 2006
33
Lamar WARD, Appellant, v. STATE of Florida, Appellee.

Case No. 2D18-1263

District Court of Appeal of Florida, Second District.

Opinion filed March 13, 2019.

**DECISION WITHOUT PUBLISHED OPINION**

Affirmed.